Dyax Corp.
300 Technology Square
Cambridge
Massachusetts
02139
U.S.A.
Phone:
617-225-2500
Fax:
617-225-2501
|
Dyax Corp. (Nasdaq: DYAX) is a biotechnology company focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications. The Company utilizes its proprietary drug discovery technology, phage display, to identify antibody, small protein and peptide compounds for clinical development.
Dyax’s lead product candidate is DX-88 (ecallantide), a recombinant small protein that is currently being evaluated for its therapeutic potential in two separate indications. On November 21, 2008, the U.S. Food and Drug Administration (FDA) accepted for filing the Company’s Biologics License Application for approval of DX-88 for the treatment of hereditary angioedema (HAE) and designated the application for Priority Review. Based on this designation, the FDA Prescription Drug User Fee Act target action date is March 23, 2009. DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S., for the treatment of acute attacks of HAE. Additionally, DX-88 is being evaluated for the prevention of blood loss during on-pump cardiothoracic surgery (CTS) through its partner, Cubist Pharmaceuticals. Dyax licensed to Cubist the intravenous formulation of DX-88 for surgical indications in North America and Europe.
DX-88 and other compounds in Dyax’s pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through its Licensing and Funded Research Program (LFRP) and has over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents.
Partnerships and Strategic Transactions:
Cubist Pharmaceuticals
DX-88 (ecallantide) in surgical indications
Sanofi-Aventis
DX-2240 and antibody phase display
Email:
ir@dyax.com
Ownership:
Web Site:
Dyax Corp.
Employees:
164
Symbol: DYAX
|